Usually, when analyzing the tumor genome by CMA, aberrations larger than 5 MB and additional microdeletions involving the CDKN2A/B, BTG1, EBF1, ETV6, ERG, IKZF1, PAX5, and RB1 genes are taken into account. Here, CDKN2A is linked to neoplasm.